ID | 119036 |
著者 |
板東, 浩
Tokushima University|Medical Research|Integrative Medicine Japan|Japan Low Carbohydrate Diet Promotion Association
KAKEN研究者をさがす
|
キーワード | sodium-glucose co-transporter-2 inhibitor (SGLT2i)
sarcopenia
visceral fat area (VFA)
skeletal muscle index (SMI)
bone mineral content (BMC)
|
資料タイプ |
学術雑誌論文
|
抄録 | Regarding pharmacological therapy for diabetes, sodium-glucose co-transporter-2 inhibitor (SGLT2i) has been in focus for various clinical efficacy. They include cardiovascular disease, chronic heart failure (CHF) and chronic kidney disease (CKD). Various discussion has been observed concerning the relationship among diabetes, frailty, sarcopenia, SGLT2i, aging and senile syndrome. By SGLT2i, weight and visceral fat area (VFA) are decreased, and the results of skeletal muscle index (SMI) and bone mineral content (BMC) vary in some reports. Using abdominal CT, bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), muscle mass and BMC have been lately studied. SGLT2i may maintain muscle mass and function.
|
掲載誌名 |
International Journal of Complementary & Alternative Medicine
|
ISSN | 23811803
|
出版者 | MedCrave Publishing
|
巻 | 15
|
号 | 4
|
開始ページ | 220
|
終了ページ | 222
|
発行日 | 2022-07-29
|
権利情報 | This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and build upon your work non-commercially.
|
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
医学系
|